Case Report: Nintedanib for Pembrolizumab-Related Pneumonitis in a Patient With Non-Small Cell Lung Cancer

Pembrolizumab, an immune checkpoint inhibitor (ICI) approved for advanced non-small cell lung cancer (NSCLC) treatment, has shown superior survival benefits. However, pembrolizumab may lead to severe immune-related adverse events (irAEs), such as checkpoint inhibitor-related pneumonitis (CIP). The r...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Xiao-Hong, Deng, Hai-Yi, Lin, Xin-Qing, Wu, Jian-Hui, Liu, Ming, Xie, Zhan-Hong, Qin, Yin-Yin, Zhou, Cheng-Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249753/
https://www.ncbi.nlm.nih.gov/pubmed/34221992
http://dx.doi.org/10.3389/fonc.2021.673877

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8249753/
https://www.ncbi.nlm.nih.gov/pubmed/34221992
http://dx.doi.org/10.3389/fonc.2021.673877

Ejemplares similares